Recently, MetaVision announced the completion of a new round of financing worth tens of millions, gaining capital support again in just two months after the financing in June this year. This round of financing was invested by Chengdu Huaxi Jinzhi Specialized and Innovative Equity Investment Partnership (Limited Partnership) (hereinafter referred to as the "Specialized and Innovative Fund") managed by Huaxi Jinzhi. Existing shareholder Innovation Works continued to increase its investment, and Win Capital served as the exclusive financial advisor. The funds from this round will be used for clinical registration, strengthening sales, brand building, and other business operations, as well as continuous R&D investment in products.

In June 2025, MetaVision completed its multi-million-dollar Series A2 financing round, exclusively invested by Jinko Junchuang, with WinX Capital serving as the exclusive financial advisor.Click to view: MetaVision completes tens of millions of yuan in A2 round financing, exclusively invested by Jinkexingchuang, leading innovation in myopia prevention and control industry）

Driven by the dual forces of the national strategic upgrade in myopia prevention and control and the development of AI technology, MetaVision leverages globally leading AI opto-neural brain modulation technology and robust clinical evidence-based medical data to directly address the core challenges of myopia prevention and control among adolescents. Starting with myopia intervention, the company is gradually building"Light-Eye-Brain" Intelligent Treatment Closed-Loop System Integrating Optical Stimulation, Neural Modulation, and AI Feedback。Centering on the technical pathway of visual neural modulation, the company has built a "strong technology + soft standards" product system to achieve "multi-point efforts":

This system is highly adaptable and can effectively match different vision conditions, usage durations, and user habits.

More crucially, this entirely new myopia prevention and control technology pathway has demonstrated efficacy surpassing traditional myopia prevention and control solutions during clinical validation.

According to multi-center research data participated by authoritative professional medical institutions such as Beijing Tongren Hospital, Sichuan Huaxi Hospital, and Wenzhou Medical University Eye Optometry Hospital,MetaVision's related products demonstrate a high level of consistency and statistical significance in controlling axial growth and slowing the progression of refraction.

In a real-world study lasting six months with nearly 200 cases, the average axial elongation in the trial group was only 0.038mm, significantly lower than 0.125mm in the control group, with some cases of refractive improvement observed.

In application scenarios, MetaVision is committed to seamlessly integrating treatment into daily life scenarios, achieving "learning while treating, playing while adjusting," and creating a new paradigm of behavior-neural integrated non-invasive treatment. Meanwhile, relying on a network covering hundreds of professional institutions and over 1000 stores, the company has initially built up...“Product-Data-Service”An integrated closed-loop system provides a solid validation foundation for the future implementation of a long-term prescription-based treatment model.

In terms of industry influence, MetaVision, in collaboration with the Eye Hospital of Wenzhou Medical University, released at the 2025 International Forum on Innovative Development of Visual Health (VisionChina2025)Technical Specifications for Remote Image Electronic Display TerminalsAnd"Technical Requirements for Visual Health of Display Products - Far-Field Electronic Display Terminals"Two group standards, which not only marks MetaVision's further consolidation of its leading position in the formulation of industry standards, but also represents an important transition from a technological innovator to an industry rule-maker.

MetaVision Co-Founder Dejiao PanExpressed: Thanks to the current round of investors for their continued optimism and firm support for MetaVision's "AI + visual neural intervention" direction.

As a team in the myopia prevention and control sector that possesses triple advantages—"underlying original technology, real-world scenario validation, and influence over industry standards"—the company has achieved remarkable commercial success: revenue in the first half of 2025 increased by over 100% year-on-year, and profitability was achieved.

This round of financing will focus on the registration and application of Class III medical devices and the iterative upgrading of core products, further implementing the strategy of "serious medical care driving consumer medical care." The company is accelerating the breakthrough of the traditional "hardware as a product" model, comprehensively upgrading to become a builder of the "visual health operating system" centered on algorithms, data, and services. This aims not only to provide 170 million Chinese teenagers with more scientifically effective myopia prevention and control solutions, achieving "screen viewing without worries," but also to create continuous growth value for investors.

Chen Feng, Head of Huaxi Jinzhi Medical InvestmentRepresents: The field of optometry has now developed into a vast and mature market, with several large market-cap companies historically created by technological transformations in this area.

Huaxi Jinzhi keenly noticed MetaVision's series of development achievements leading the new generation of technological trends in the optometry field. Its differentiated products, supported by clinical data, naturally integrate into learning and entertainment scenarios, gradually building up high industry barriers within the end-user system. Meanwhile, MetaVision’s business model has been preliminarily validated by the market, fully demonstrating its extreme scarcity and high growth potential.

Senior Investment Director of Innovation Works, Li JiapengMetaVision's "Longitudinal Light Screen" product has creatively utilized AI and digital methods for myopia prevention and control, gradually gaining deep recognition from optometrists and users.

The company has steadfastly advanced multiple clinical trials on digital myopia prevention and control technologies, achieving excellent short-term and long-term clinical outcomes.

At the same time, MetaVision has successfully provided users with personalized myopia prevention and control management services covering the entire myopia cycle this year, based on its digital product for long-distance light screens, enhanced by AI assistance. This has further strengthened the effectiveness of real-world myopia prevention and control for users, increasing satisfaction.

In the long term, MetaVision is expected to become a leading player in the optometry field, driven by a dual engine of "innovative products + innovative service model."